A Phase 2 interventional study of transcranial alternating current stimulation (tACS) in Anxiety Disorders, sponsored by NeuroCognitive and Behavioral Institute Clinical Research Foundation. Recruiting at 1 site in United States. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.
Sponsored by NeuroCognitive and Behavioral Institute Clinical Research Foundation · Phase 2, Interventional, and Treatment
This is a clinical research trial exploring the efficacy of non-invasive neuromodulation (NM) intervention in the treatment of anxiety. The NM used in this study consists of 25 minutes of 5 hz transcranial alternating current stimulation (tACS) titrated up to 2mA targeting the anterolateral amygdala across 12 treatment sessions with a 3-4 week time period. The studied population includes patients with the following anxiety disorders: generalized anxiety disorder (GAD), social anxiety disorder (SAD), separation anxiety disorder of childhood, and post-traumatic stress disorder (PTSD). Participants will be randomly assigned to tACS or sham, cross-over, then followed by an optional open-label extension phase.
4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.
This study's planned enrollment of 40 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →This is the only study on the registry with NeuroCognitive and Behavioral Institute Clinical Research Foundation as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: transcranial alternating current stimulation (tACS)
Device: transcranial alternating current stimulation (tACS)
2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
Response rate informed by Beck Anxiety Inventory (BAI)
BAI is a self-rated scale, with scores ranging from 0 to 63. We will calculate the treatment response rate as (pre-treatment BAI minus post-treatment BAI)/pre-treatment BAI
Time frame: 12 treatment sessions, with 3-4 sessions/week, and the time frame for each participant is 3 to 4 weeks.
Hamilton Anxiety Rating Scale (HAMA)
HAMA is a clinician-rated scale, with scores ranging from 0 to 56. We will calculate the treatment response rate as (pre-treatment HAMA minus post-treatment HAMA)/pre-treatment HAMA. We will compute the average of response rates from HAMA and BAI as the final outcome measure.
Time frame: 12 treatment sessions, with 3-4 sessions/week, and the time frame for each participant is 3 to 4 weeks.
PTSD Checklist (PCL) for PTSD cohort
For the PTSD patients, in addition to anxiety measurement, we will also use PCL (ranges from 0 to 80) to register the symptom severity change. Again, the outcome measure is the treatment response rate, defined as pre-treatment PCL minus post-treatment PCL)/pre-treatment PCL
Time frame: 12 treatment sessions, with 3-4 sessions/week, and the time frame for each participant is 3 to 4 weeks.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.